Formulation and in-vitro evaluations of doxorubicin loaded polymerized magnetic nanocarriers for liver cancer cells
Journal
Journal of the Taiwan Institute of Chemical Engineers
Series/Report No.
Journal of the Taiwan Institute of Chemical Engineers
Journal Volume
126
Start Page
278-287
ISSN
1876-1070
Date Issued
2021-09-01
Author(s)
Abstract
Background: Liver cancer is the third most common cause of cancer deaths globally. Regrettably, its treatment is limited due to insufficient treatment options and side effects caused by chemotherapy which is the common treatment method. Thus, the main aim of the study was the synthesis of nanocarriers composed of dextran modified iron oxide nanoparticles for doxorubicin delivery (IONP@Dex@DOX) in liver cancer treatment to overcome the limitations of chemotherapy Methods: The IONP@Dex nanocarriers were first synthesized via solvothermal method and then characterized using several analytical instruments. Significant findings: XRD and HR–TEM demonstrated spherical core-shelled, well-dispersed, and highly crystalline magnetite (311) nanocarriers with sizes ranging between 10 and 15 nm. Both IONPs and IONP@Dex nanocarriers (42.50 and 33.40 emu/g) exhibited a saturation magnetization high enough to be magnetically controlled throughout the body. A biocompatibility of above 80% was confirmed through in-vitro cell viability studies using the 3-(4,5-dimethylthiazole-2-yl)2,5-diphenyltetrazolium bromide (MTT)-based assay at 24 and 48 h against HEK293T and HepG2 cells. The results demonstrated nontoxic nanoparticles with cell viability above 80%. Interestingly, upon drug conjugation, a drastic reduction in the viability of cancerous cells was observed. Exposure of cells treated with the drug loaded nanocarrier to an external magnetic field (EMF) demonstrated an additional decrease in cell viability.
SDGs
Publisher
Elsevier BV
Type
journal article